ROCKVILLE AND BALTIMORE, MARYLAND, February 18, 2014 – BioHealth Innovation, Inc. (BHI) and China Fortune Land Development Co., Ltd. (CFLD) announced today that they have signed an agreement to jointly manage a newly created Entrepreneur-In-Residence (EIR) position to be located at the BHI headquarters in Rockville, Maryland. This first-of-its-kind position will lead in the scouting of technologies and partnership opportunities in life science hubs in the U.S. and China.
“We’re very pleased to advance our partnership with BHI,” said Mr. Hu Zhen Yu, Vice President for CFLD, a company specializing in investment and operation of industrial areas in China, including science parks. “Our organizations first had a chance to connect in person when BHI’s CEO Rich Bendis traveled with a delegation from Montgomery County, Maryland, to China. Now, we look forward to filling this new EIR position, which will help to identify talented businesses and commercial prospects for our collaborative efforts.”
The new EIR will evaluate life science technologies in both China and the U.S. markets; provide a strategic plan for start-up companies; advise on opportunities for new ventures; and lead the commercial strategy for mature assets. This would be BHI’s 5th EIR since the program’s inception two years ago.
Where’s the nation’s second largest concentration of academic, federal and private sector research spending? California? Massachusetts? According to the National Science Foundation, it’s Maryland, equating to billions of dollars in research investment in the Maryland economy. First place New Mexico has a relatively small rural population and presence of two major federal nuclear research labs.
But Maryland has something New Mexico doesn’t — proximity to Washington, D.C.
Washington is home to the nation’s government, but also the National Academies, technology trade associations, international corporations, embassies, media, regulatory agencies, foundations, and science agencies.
Bethesda Blues and Jazz – 7719 Wisconsin Avenue, Bethesda, MD 20814
What’s next for Montgomery County? The potential for livable work, live and play environments on Metro abound. But what about the business community? What is it going to take to build an innovation economy? Is Montgomery County going to become the next tech hub?
Join us for a very special morning event featuring some of the brightest and most influential business and real estate leaders as they discuss some of the most dramatic decisions that this region will face in the upcoming year. Sign up now to join leaders of the Maryland business region for an important morning of discussion and networking!
BioHealth Innovation, Inc. (BHI), a Montgomery County, Maryland innovation intermediary which translates market-relevant research into commercial success by bringing together among other things management, funding, and markets, is seeking an experienced life science professional with entrepreneurial experience to serve as its Entrepreneur-in-Residence (EIR) financially supported by the China Fortune Land Development Company, LTD (CFLD), focused on advancing China-U.S. partnerships. The EIR will collaborate with a life science commercialization expert who has an interest in relocating to the Peptide Valley to assist CFLD in Chinese life science commercialization. BHI will work with the CFLD EIR on this recruitment as well as provide training to them. The EIR will lead in the scouting of technologies in both markets with a preliminary focus on therapeutic vaccines, antibodies, medical devices, proteins and peptides and diagnostics. Further, the EIR will build partnerships in life science hubs in the U.S. and China which support the progression of these technologies for manufacturing or at the preclinical testing stage of development, the primary focus of the Peptide Valley. This EIR will evaluate life science technologies in both markets, provide a strategic plan for start-up companies, advise on opportunities for new ventures, and lead the commercial strategy for mature assets. The EIR will oversee primary and secondary research and will provide strategic recommendations and insights on the direction of potential assets that have potential for Chinese commercialization in the Peptide Valley or other CFLD research parks.
A recent third-party economic development impact study conducted by Battelle Technology Partnership Practice (TPP), the world’s largest non-profit research and development organization, has found that the Maryland Technology Development Corporation (TEDCO) currently supports more than $565.9 million in economic contributions and more than 2,835 jobs in the State of Maryland annually, earning $200.5 million in salaries with estimated State and local government revenues of $22.8 million. The study also determined the economic contribution of TEDCO programs is projected to grow to $910.3 million and support a total of 4,527 jobs by 2018. These jobs will earn $320.3 million in salaries with estimated State and local government revenues of $36.6 million.
Bethesda-based Sucampo named former MedImmune president Peter Greenleaf to serve as the company’s chief executive starting next month, according to a news release.
The appointment brings a high-profile name to the biotechnology firm as it looks to commercialize products for glaucoma and constipation, as well as develop additional drugs to treat eye and digestive issues.
MedImmune, the global biologics research and development arm of AstraZeneca, announced it has entered into a three-year collaboration with the Clinical and Translational Science Institute (CTSI) at the University of California, San Francisco (UCSF). The collaboration will focus on CTSI’s Catalyst Awards program, which solicits applications from University scientists who wish to move their translational research beyond the bench and into product development.
This marks the first industrial partnership for CTSI’s Catalyst Awards program’s therapeutic track, which focuses specifically on discovery and development of patient treatment options. The collaboration will benefit both MedImmune’s biologics and AstraZeneca’s small molecule portfolios and will call for proposals in therapeutic areas of interest to MedImmune and AstraZeneca, including cardiovascular and metabolic disease; oncology; respiratory, inflammation and autoimmunity; neuroscience and infectious disease.
Rockville-based MacroGenics Inc. plans to sell 2.5 million shares in a secondary offering, the bulk of which would go toward advancing the biotech’s oncology drug candidates through the clinic and expanding its manufacturing capacity.
Much like in MacroGenics’ October initial public offering, the chief purpose of this offering is to fund the pipeline, with 1.5 million shares offered by the company and another 1 million shares coming from selling shareholders.
Out of 260 applicants, 41 start-ups have advanced in the second annual InvestMaryland Challenge, the Maryland Department of Business and Economic Development (DBED) announced today.
The early-stage business competition—with awards provided by DBED’s Maryland Venture Fund, the BioMaryland Center and other sponsors—seeks to grow entrepreneurship and innovation in the State.
QIAGEN N.V. QGEN +0.76% (frankfurt prime standard:QIA) today announced the launch plans of several novel products designed to significantly reduce the challenges of the most significant bottlenecks in next-generation sequencing (NGS): sample preparation and bioinformatics. The solutions will enable NGS users to generate more valuable insights from any sample. The new products add to QIAGEN’s rapidly expanding portfolio of ‘universal’ solutions designed to run with any NGS platform, including QIAGEN’s GeneReader™ platform, which is being prepared for launch in 2014. Several of QIAGEN’s new NGS products will be introduced to genomics researchers this week at the 15th annual Advances in Genome Biology and Technology (AGBT) meeting in Marco Island, Florida.
The Tech Council of Maryland (TCM), Maryland’s largest technology trade association with more than 400 life science and technology members employing over 200,000 in the region, today announced that individuals from Hewlett-Packard Co., Johns Hopkins University, MedImmune, RCM&D and SoBran Inc. were named to the association’s board of directors.
“We are excited to have this impressive group of individuals on the TCM board,” said Phil Schiff, TCM’s CEO. “Their individual and collective expertise will be invaluable as the association evolves to address the changing needs of our membership.”
The DC regional Innovation Corps (I-Corps) program is now accepting university research teams from the DC, MD, and VA area for the 5-week Lean LaunchPad, technology commercialization and customer development workshop beginning March 24th. UMD is the lead institution running the NSF-funded program, and as such, teams from UMD will be given priority in this program. Interested teams can learn more and apply at http://www.dcicorps.org/. Feel free to contact info@dcicorps.org or (240) 319-9594 if you have any questions.
Looking beyond the small-molecule drugs and biologic treatments that have dominated therapeutic development over the past generation, GlaxoSmithKline’s ($GSK) all-encompassing R&D department is trying to get a jump on the future of medicine, and research chief Moncef Slaoui is betting that there’s a great deal of promise in drug-mimicking electronics.
By Suzanne Raheb, Corporate Supplier Diversity Leader, Lockheed Martin Corporation
Whether working as a subcontractor or a technology mentor, Lockheed Martin provides small businesses with various assistance during different phases of their SBIR/STTR projects. This includes supporting technology requirements, evaluation, co-development, and insertion into larger systems.
In 2008, Thierry Merquiol joined a crowdfunding effort to produce the first album of a little-known French singer named Grégoire. The investment paid off, Grégoire became a hit, and the experience inspired Merquiol to set up a similar crowdfunding platform for undiscovered companies. Nearly five years later, Merquiol and his business partner’s group, the Toulouse, France-based WiSeed, have helped finance 33 startup firms, including four in biotechnology. “Ours is democratization of equity funding,” said WiSeed associate Souleymane-Jean Galadima.
Illumina, Inc. today announced the launch of the Illumina Accelerator Program, the world’s first business accelerator focused solely on creating an innovation ecosystem for the genomics industry. Its goal is to speed the time to market and lower the barriers to entry for entrepreneurs, start-ups and early stage companies working on scientifically and commercially promising next-generation sequencing (NGS) applications.
Through the accelerator’s six-month program, Illumina will provide invited participants with technology and business guidance and $100,000 in support, including access to sequencing systems and reagents, as well as fully operational lab space in close proximity to the company’s planned R&D facilities in San Francisco’s Mission Bay. Initial partners include prominent technology investor Yuri Milner, who will offer each participating company $100,000 in exchange for convertible notes, and Silicon Valley Bank, which intends to provide banking services and credit to each participating company.
The pharmaceutical industry’s dependence on universities and small biotechs as the source of innovation is laid bare in an analysis of the origin of all the novel drugs approved by the European Medicines Agency (EMA) in the three years from 2010 – 2012.
The analysis shows that 49 per cent of the products granted marketing authorisation during this time were originally discovered by the in-house efforts of pharma companies, with the remaining 51 per cent originating elsewhere. However, of the 94 products that received approval, 87 per cent were owned by pharma companies at the point the license was granted.
Through the Open Innovation Challenge, the American Heart Association hopes to get closer to its goal of improving Americans’ cardiovascular health by 20 percent by 2020.
The key to crowdfunding success? Pull at the heartstrings of your audience.
That’s what the New York City affiliate of the American Heart Association aims to do in its first-ever Open Innovation Challenge, a program that is part of the AHA’s Health Science Innovation and Investment Forum.
Based on an exhaustive search of Apple’s AppStore and the Google Play store in September 2013, MobiHealthNews found 205 apps that were “hospital-branded” and intended for use by consumers or patients. By that we mean simply that the hospital has put its name on these apps. For this special MobiHealthNews In-Depth we are publicly sharing for the first time the topline findings from our report. If you’d like to learn more about the history of mobile initiatives at US hospitals or would like access to the entire list of 205 hospital-branded apps for patients — head over to our research store to get your copy today.
One of IBM’s first app ecosystem partners for Watson, the health optimization company Welltok Inc., became the first firm to benefit from a $100 million venture fund IBM established to promote the use of its cognitive computing technology.
Welltok has raised $22.1 million in Series C funding led by New Enterprise Associates (NEA) with new participation from IBM and Qualcomm Ventures. This brings Welltok’s funding in the last nine months to more than $40 million.
In a recent post at In the Pipeline, Derek Lowe answers a reader’s question about how best to promote drug discover in India. Given my research on the matter, I figured I would try and provide an answer as well.
In Scientific American’s Worldview, I have been ranking national biotechnology industries for the past five years. When I was recently in New Delhi I presented the Indian innovation figures and asked the audience to guess where they ranked. Much to their amazement, India was ranked with the bottom five of the 50+ countries assessed. The issues are myriad — poor patent protection, infrastructure problems, an insufficient quantity (not quality!) of skilled workers, etc.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
